COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO

105
19
Favorite

COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO

Reuters2021-07-07

July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

105

Report

Comment（19）

BlueDragon
·2021-07-08
Ok
Reply
Like
Report
Sharoncpg
·2021-07-08
Ok
Reply
2
Report
Sharoncpg
·2021-07-08
Ok
Reply
2
Report
mizseah
·2021-07-08
Well done its good news
Reply
1
Report
Moon168
·2021-07-08
[Cry] [Cry]
Reply
1
Report
carrotman
·2021-07-08
Can they still make it? Considering a few vaccines are already in the market.
Reply
Like
Report
Fold Replies
- Rteo:
  Late To Market
  2021-07-08
  Reply
  Report
Philipoo
·2021-07-08
Wow ?
Reply
2
Report
Sunmi
·2021-07-08
Vials order leadtime was approx 12 months during first half of 2020 last year. In demand.
Reply
2
Report
Terry_Tey
·2021-07-08
???
Reply
3
Report
addyloh
·2021-07-07
Pls like
Reply
2
Report
evwaeng
·2021-07-07
vaccine mkt saturated
Reply
1
Report
SherryVJ
·2021-07-07
Tell me your opinion about this news...
Reply
2
Report
Fold Replies
- Sunmi:
  Vials order leadtime was approx 12 mths in early 2020. some claim that vaccines mkt r saturated but vaccine demand is still high hence if stock valuation is reasonable, it will be worth to look into.
  2021-07-08
  Reply
  Report
kiraro
·2021-07-07
Latest
Reply
2
Report
miyakos
·2021-07-07
Latest
Reply
2
Report
Fold Replies
- CindyKuoh:
  ?
  2021-07-07
  Reply
  Report
Alfred1007
·2021-07-07
Wow..it worth 7 billion
Reply
5
Report
Fold Replies
- Missypampam:
  ?
  2021-07-07
  Reply
  Report
DandanC
·2021-07-07
Ok
Reply
2
Report
Anni001
·2021-07-07
Please help like and commentThank you [微笑]
Reply
4
Report
Fold Replies
- super7white:
  like and comment
  2021-07-07
  Reply
  Report
Wpeiro87
·2021-07-07
Like and comment
Reply
3
Report
Fold Replies
- Anni001:
  Please comment like and comment back too
  2021-07-07
  Reply
  Report
SNee
·2021-07-07
[微笑]
Reply
2
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1128740137?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-07-07 22:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128740137","market":"us","top_or_hot":-1,"title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","media":"Reuters","content":"<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":".IXIC","symbol_name":"NASDAQ Composite","start_time":0,"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","article_id":"1128740137","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","pubTimestamp":1625668639,"sourceInfo":null,"weMediaInfo":null,"summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","collect":0,"end_time":0,"defaultTopTitle":"reuters.com","property":[],"viewcount":null,"language":"en","relate_stocks":{".IXIC":"NASDAQ Composite"},"translate_title":"新冠肺炎疫苗瓶制造商Stevanato在美国首次公开募股估值为7英镑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{".IXIC":0.9},"content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":149112955,"gmtCreate":1625708988277,"gmtModify":1703746821149,"author":{"id":"4087932884013320","authorId":"4087932884013320","name":"BlueDragon","avatar":"https://static.tigerbbs.com/431c326e19a16844e147d10866565f27","vip":1,"crmLevel":2,"crmLevelSwitch":1,"authorIdStr":"4087932884013320","idStr":"4087932884013320"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/149112955","repostId":1128740137,"repostType":4,"repost":{"id":"1128740137","pubTimestamp":1625668639,"share":"https://ttm.financial/m/news/1128740137?lang=&edition=fundamental","pubTime":"2021-07-07 22:37","market":"us","language":"en","title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","media":"Reuters","summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128740137","content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":149911725,"gmtCreate":1625700879467,"gmtModify":1703746532725,"author":{"id":"3577610300187690","authorId":"3577610300187690","name":"Sharoncpg","avatar":"https://static.tigerbbs.com/9c1567648b16c497608badcc662d4756","vip":1,"crmLevel":6,"crmLevelSwitch":0,"authorIdStr":"3577610300187690","idStr":"3577610300187690"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/149911725","repostId":1128740137,"repostType":4,"repost":{"id":"1128740137","pubTimestamp":1625668639,"share":"https://ttm.financial/m/news/1128740137?lang=&edition=fundamental","pubTime":"2021-07-07 22:37","market":"us","language":"en","title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","media":"Reuters","summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128740137","content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":149913930,"gmtCreate":1625700805420,"gmtModify":1703746529929,"author":{"id":"3577610300187690","authorId":"3577610300187690","name":"Sharoncpg","avatar":"https://static.tigerbbs.com/9c1567648b16c497608badcc662d4756","vip":1,"crmLevel":6,"crmLevelSwitch":0,"authorIdStr":"3577610300187690","idStr":"3577610300187690"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/149913930","repostId":1128740137,"repostType":4,"repost":{"id":"1128740137","pubTimestamp":1625668639,"share":"https://ttm.financial/m/news/1128740137?lang=&edition=fundamental","pubTime":"2021-07-07 22:37","market":"us","language":"en","title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","media":"Reuters","summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128740137","content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":149994465,"gmtCreate":1625700288057,"gmtModify":1703746510834,"author":{"id":"3573873419404517","authorId":"3573873419404517","name":"mizseah","avatar":"https://static.tigerbbs.com/ac4cc904a19ed963f6dceca76fd16300","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3573873419404517","idStr":"3573873419404517"},"htmlText":"Well done its good&nbsp;news","listText":"Well done its good&nbsp;news","text":"Well done its good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/149994465","repostId":1128740137,"repostType":4,"repost":{"id":"1128740137","pubTimestamp":1625668639,"share":"https://ttm.financial/m/news/1128740137?lang=&edition=fundamental","pubTime":"2021-07-07 22:37","market":"us","language":"en","title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","media":"Reuters","summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128740137","content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":149905829,"gmtCreate":1625699654461,"gmtModify":1703746496129,"author":{"id":"4088063093928140","authorId":"4088063093928140","name":"Moon168","avatar":"https://static.tigerbbs.com/33a1d014ad313b464a79e0ff58f37331","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4088063093928140","idStr":"4088063093928140"},"htmlText":"[Cry]&nbsp;[Cry]&nbsp;","listText":"[Cry]&nbsp;[Cry]&nbsp;","text":"[Cry] [Cry]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/149905829","repostId":1128740137,"repostType":4,"repost":{"id":"1128740137","pubTimestamp":1625668639,"share":"https://ttm.financial/m/news/1128740137?lang=&edition=fundamental","pubTime":"2021-07-07 22:37","market":"us","language":"en","title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","media":"Reuters","summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128740137","content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":149072515,"gmtCreate":1625699016037,"gmtModify":1703746479787,"author":{"id":"3564197930660816","authorId":"3564197930660816","name":"carrotman","avatar":"https://static.tigerbbs.com/9b29e1032c7343cf14e78c210f93267f","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3564197930660816","idStr":"3564197930660816"},"htmlText":"Can they still make it? Considering a few vaccines are already in the market.","listText":"Can they still make it? Considering a few vaccines are already in the market.","text":"Can they still make it? Considering a few vaccines are already in the market.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/149072515","repostId":1128740137,"repostType":4,"repost":{"id":"1128740137","pubTimestamp":1625668639,"share":"https://ttm.financial/m/news/1128740137?lang=&edition=fundamental","pubTime":"2021-07-07 22:37","market":"us","language":"en","title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","media":"Reuters","summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128740137","content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5153982,"gmtCreate":1625700976901,"gmtModify":1663230671946,"authorId":3582595806100338,"author":{"id":3582595806100338,"idStr":"3582595806100338","authorId":3582595806100338,"name":"Rteo","avatar":"https://static.tigerbbs.com/ba4c61a94c707cd25f18400b8cc52a4c","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.22","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":149072515,"type":1,"supId":0,"prevId":0,"content":"Late To Market","text":"Late To Market","html":"Late To Market"}],"langContent":"EN"},{"id":149021902,"gmtCreate":1625696450306,"gmtModify":1703746432606,"author":{"id":"4087525706477120","authorId":"4087525706477120","name":"Philipoo","avatar":"https://static.tigerbbs.com/6e8a19c2e2e38459c077e596babeb0d6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4087525706477120","idStr":"4087525706477120"},"htmlText":"Wow ?&nbsp;","listText":"Wow ?&nbsp;","text":"Wow ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/149021902","repostId":1128740137,"repostType":4,"repost":{"id":"1128740137","pubTimestamp":1625668639,"share":"https://ttm.financial/m/news/1128740137?lang=&edition=fundamental","pubTime":"2021-07-07 22:37","market":"us","language":"en","title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","media":"Reuters","summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128740137","content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":140779230,"gmtCreate":1625678188920,"gmtModify":1703746334330,"author":{"id":"3543360252990222","authorId":"3543360252990222","name":"Sunmi","avatar":"https://static.tigerbbs.com/9d876feae85a19464db5378bff465d79","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3543360252990222","idStr":"3543360252990222"},"htmlText":"Vials order leadtime was approx 12 months during first half of 2020 last year.&nbsp; In demand.","listText":"Vials order leadtime was approx 12 months during first half of 2020 last year.&nbsp; In demand.","text":"Vials order leadtime was approx 12 months during first half of 2020 last year. In demand.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/140779230","repostId":1128740137,"repostType":4,"repost":{"id":"1128740137","pubTimestamp":1625668639,"share":"https://ttm.financial/m/news/1128740137?lang=&edition=fundamental","pubTime":"2021-07-07 22:37","market":"us","language":"en","title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","media":"Reuters","summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128740137","content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":140720450,"gmtCreate":1625674685370,"gmtModify":1703746287881,"author":{"id":"3569246059375185","authorId":"3569246059375185","name":"Terry_Tey","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3569246059375185","idStr":"3569246059375185"},"htmlText":"???","listText":"???","text":"???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/140720450","repostId":1128740137,"repostType":4,"repost":{"id":"1128740137","pubTimestamp":1625668639,"share":"https://ttm.financial/m/news/1128740137?lang=&edition=fundamental","pubTime":"2021-07-07 22:37","market":"us","language":"en","title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","media":"Reuters","summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128740137","content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":140797265,"gmtCreate":1625672099757,"gmtModify":1703746231806,"author":{"id":"4087969381788350","authorId":"4087969381788350","name":"addyloh","avatar":"https://static.tigerbbs.com/a38dc3736886e9760c56bc8fd1b2dee4","vip":1,"crmLevel":2,"crmLevelSwitch":1,"authorIdStr":"4087969381788350","idStr":"4087969381788350"},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/140797265","repostId":1128740137,"repostType":4,"repost":{"id":"1128740137","pubTimestamp":1625668639,"share":"https://ttm.financial/m/news/1128740137?lang=&edition=fundamental","pubTime":"2021-07-07 22:37","market":"us","language":"en","title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","media":"Reuters","summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128740137","content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":140444216,"gmtCreate":1625670506435,"gmtModify":1703746187575,"author":{"id":"3570269548399266","authorId":"3570269548399266","name":"evwaeng","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3570269548399266","idStr":"3570269548399266"},"htmlText":"vaccine mkt saturated&nbsp;","listText":"vaccine mkt saturated&nbsp;","text":"vaccine mkt saturated","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/140444216","repostId":1128740137,"repostType":4,"repost":{"id":"1128740137","pubTimestamp":1625668639,"share":"https://ttm.financial/m/news/1128740137?lang=&edition=fundamental","pubTime":"2021-07-07 22:37","market":"us","language":"en","title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","media":"Reuters","summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128740137","content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":140445045,"gmtCreate":1625670422387,"gmtModify":1703746187743,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://community-static.tradeup.com/news/1881722e980e541f3c66ed217d5b91c6","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":4,"crmLevelSwitch":1,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/140445045","repostId":1128740137,"repostType":4,"repost":{"id":"1128740137","pubTimestamp":1625668639,"share":"https://ttm.financial/m/news/1128740137?lang=&edition=fundamental","pubTime":"2021-07-07 22:37","market":"us","language":"en","title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","media":"Reuters","summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128740137","content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5152386,"gmtCreate":1625678679486,"gmtModify":1663230665947,"authorId":3543360252990222,"author":{"id":3543360252990222,"idStr":"3543360252990222","authorId":3543360252990222,"name":"Sunmi","avatar":"https://static.tigerbbs.com/9d876feae85a19464db5378bff465d79","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":140445045,"type":1,"supId":0,"prevId":0,"content":"Vials order leadtime was approx 12 mths in early 2020. some claim that vaccines mkt r saturated but vaccine demand is still high hence if stock valuation is reasonable, it will be worth to look into.","text":"Vials order leadtime was approx 12 mths in early 2020. some claim that vaccines mkt r saturated but vaccine demand is still high hence if stock valuation is reasonable, it will be worth to look into.","html":"Vials order leadtime was approx 12 mths in early 2020. some claim that vaccines mkt r saturated but vaccine demand is still high hence if stock valuation is reasonable, it will be worth to look into."}],"langContent":"EN"},{"id":140443670,"gmtCreate":1625670263290,"gmtModify":1703746179964,"author":{"id":"4088322427092430","authorId":"4088322427092430","name":"kiraro","avatar":"https://static.tigerbbs.com/4fcfe68b738dbc616cdef43f590197e4","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4088322427092430","idStr":"4088322427092430"},"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/140443670","repostId":1128740137,"repostType":4,"repost":{"id":"1128740137","pubTimestamp":1625668639,"share":"https://ttm.financial/m/news/1128740137?lang=&edition=fundamental","pubTime":"2021-07-07 22:37","market":"us","language":"en","title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","media":"Reuters","summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128740137","content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":140459222,"gmtCreate":1625669756066,"gmtModify":1703746165090,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4088416347172780","idStr":"4088416347172780"},"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/140459222","repostId":1128740137,"repostType":4,"repost":{"id":"1128740137","pubTimestamp":1625668639,"share":"https://ttm.financial/m/news/1128740137?lang=&edition=fundamental","pubTime":"2021-07-07 22:37","market":"us","language":"en","title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","media":"Reuters","summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128740137","content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5151236,"gmtCreate":1625670215440,"gmtModify":1663230659327,"authorId":4087480559772270,"author":{"id":4087480559772270,"idStr":"4087480559772270","authorId":4087480559772270,"name":"CindyKuoh","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":140459222,"type":1,"supId":0,"prevId":0,"content":"?","text":"?","html":"?"}],"langContent":"EN"},{"id":140421964,"gmtCreate":1625669396258,"gmtModify":1703746153979,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3570656625926041","idStr":"3570656625926041"},"htmlText":"Wow..it worth 7 billion","listText":"Wow..it worth 7 billion","text":"Wow..it worth 7 billion","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/140421964","repostId":1128740137,"repostType":4,"repost":{"id":"1128740137","pubTimestamp":1625668639,"share":"https://ttm.financial/m/news/1128740137?lang=&edition=fundamental","pubTime":"2021-07-07 22:37","market":"us","language":"en","title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","media":"Reuters","summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128740137","content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5151164,"gmtCreate":1625669843505,"gmtModify":1663230658943,"authorId":3576253972603112,"author":{"id":3576253972603112,"idStr":"3576253972603112","authorId":3576253972603112,"name":"Missypampam","avatar":"https://static.tigerbbs.com/25229e3836d82fa58ebf76e52af13677","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":140421964,"type":1,"supId":0,"prevId":0,"content":"?","text":"?","html":"?"}],"langContent":"EN"},{"id":140464847,"gmtCreate":1625669234089,"gmtModify":1703746147313,"author":{"id":"3581765192280157","authorId":"3581765192280157","name":"DandanC","avatar":"https://static.tigerbbs.com/e2a11bfd02ad81137e21e534e8a35232","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3581765192280157","idStr":"3581765192280157"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/140464847","repostId":1128740137,"repostType":4,"repost":{"id":"1128740137","pubTimestamp":1625668639,"share":"https://ttm.financial/m/news/1128740137?lang=&edition=fundamental","pubTime":"2021-07-07 22:37","market":"us","language":"en","title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","media":"Reuters","summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128740137","content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":140484556,"gmtCreate":1625668938475,"gmtModify":1703746133149,"author":{"id":"3581489684162254","authorId":"3581489684162254","name":"Anni001","avatar":"https://static.itradeup.com/news/d5be87dbe18cee1e85c9c2cb39fe99ce","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3581489684162254","idStr":"3581489684162254"},"htmlText":"Please help like and commentThank you&nbsp;[微笑]&nbsp;","listText":"Please help like and commentThank you&nbsp;[微笑]&nbsp;","text":"Please help like and commentThank you [微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/140484556","repostId":1128740137,"repostType":4,"repost":{"id":"1128740137","pubTimestamp":1625668639,"share":"https://ttm.financial/m/news/1128740137?lang=&edition=fundamental","pubTime":"2021-07-07 22:37","market":"us","language":"en","title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","media":"Reuters","summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128740137","content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5151025,"gmtCreate":1625669202746,"gmtModify":1635234932841,"authorId":3559384539347171,"author":{"id":3559384539347171,"idStr":"3559384539347171","authorId":3559384539347171,"name":"super7white","avatar":"https://static.tigerbbs.com/33a044b05848b03ffdfc1e175c1588f4","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":140484556,"type":1,"supId":0,"prevId":0,"content":"like and comment","text":"like and comment","html":"like and comment"}],"langContent":"CN"},{"id":140488519,"gmtCreate":1625668826731,"gmtModify":1703746127260,"author":{"id":"3572737452508251","authorId":"3572737452508251","name":"Wpeiro87","avatar":"https://static.tigerbbs.com/91842112bbc8c3bf84f8ffb3950350bd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3572737452508251","idStr":"3572737452508251"},"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/140488519","repostId":1128740137,"repostType":4,"repost":{"id":"1128740137","pubTimestamp":1625668639,"share":"https://ttm.financial/m/news/1128740137?lang=&edition=fundamental","pubTime":"2021-07-07 22:37","market":"us","language":"en","title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","media":"Reuters","summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128740137","content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5150945,"gmtCreate":1625668923266,"gmtModify":1663230661342,"authorId":3581489684162254,"author":{"id":3581489684162254,"idStr":"3581489684162254","authorId":3581489684162254,"name":"Anni001","avatar":"https://static.itradeup.com/news/d5be87dbe18cee1e85c9c2cb39fe99ce","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":140488519,"type":1,"supId":0,"prevId":0,"content":"Please comment like and comment back too","text":"Please comment like and comment back too","html":"Please comment like and comment back too"}],"langContent":"EN"},{"id":140488947,"gmtCreate":1625668806889,"gmtModify":1703746126593,"author":{"id":"4088765138335240","authorId":"4088765138335240","name":"SNee","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4088765138335240","idStr":"4088765138335240"},"htmlText":"[微笑]&nbsp;","listText":"[微笑]&nbsp;","text":"[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/140488947","repostId":1128740137,"repostType":4,"repost":{"id":"1128740137","pubTimestamp":1625668639,"share":"https://ttm.financial/m/news/1128740137?lang=&edition=fundamental","pubTime":"2021-07-07 22:37","market":"us","language":"en","title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","media":"Reuters","summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128740137","content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":105,"commentSize":19,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}